University of Delaware Biosafety Committee
Meeting Minutes- June 5, 2025 11:30am-1:30pm
Hybrid- In Person and Zoom Meeting

| Present | Member |
|---|---|
| X | Dr. Jennifer Biddle, School of Marine Science and Public Policy |
| X | Dr. Erin Brannick, Animal and Food Sciences, Animal Expert, IBC Chair |
| X | Ms. Renee Brown, Research Office |
| X | Dr. Brandon Calitree, Environmental Health and Safety |
| X | Dr. Nicole Donofrio, Plant and Soil Sciences, Plant Expert |
| X | Ms. Michelle Ferguson, Biosafety Officer, Environmental Health and Safety |
| | Ms. Michelle Hamilton, Community Member |
| | Mr. Norm Henry, Community Member |
| | Dr. April Kloxin, Chemical and Biomolecular Engineering |
| X | Dr. Anja Nohe, Biological Sciences |
| X | Dr. Mark Parcells, Animal and Food Sciences, Animal Expert |
| X | Ms. Margaret (Meg) Roth, School of Nursing |
| X | Dr. Stephen Streatfield, Plant and Soil Sciences, Plant Expert |
| X | Ms. Heather Walters, Medical and Molecular Sciences |
| X | Dr. Neal Zondlo, Chemistry and Biochemistry |

A quorum was met for this meeting.

**Guests Present**
Ms. Kayla Velazquez, Environmental Health and Safety

**Call to Order**

- Dr. Brannick called the meeting to order at 11:30am. Minutes from April 3, 2025 meeting were approved. (12 for/0 against)

**Committee Review of Recombinant DNA Registrations**

- The Committee reviewed the list of exempt category research. Four protocols met this category (25-028, 25-030, 25-031, 25-032). Dr. Zondlo moved to approve and accept all registrations as listed and Ms. Roth seconded. The vote was unanimous in favor of acceptance.

- The non-exempt research was reviewed next. One experiment met this category. 25-029 was reviewed as indicated on the Review Form on page 3. Dr. Zondlo moved to approve the protocol, and Dr. Donofrio seconded. The vote was unanimous in favor of acceptance.

**Incident Review**

- The committee reviewed two incidents, I25-008, I25-009 that were deemed non-reportable according to the NIH Guidelines.

**Program Summaries and Ongoing Oversight**

The committee discussed updates within the select agent program, bloodborne pathogen program and biosafety program.

- Three new members have been added to the select agent program and are either approved or in process of being approved.
- Discussion of registration compliance for the BBP and Biosafety programs, as well as training deficiencies were presented to the committee. Individuals have been contacted monthly regarding their outstanding items for each program.

**Old Business**

- The Committee discussed the NIH announcement regarding maximum transparency for IBC minutes and Rosters. Options for compliance were discussed to be followed up by next meeting.

**New Business**

- UBC SOP updates- The Committee will review the UBC SOP and leave comments. Voting for the revised SOP will be done at the next meeting.

**IBC Training**

- The Committee discussed the DURC executive order from the White House and steps to move forward once the update is implemented.

**Public Comments**

- There were no public comments for this meeting.

**Adjournment**

- Dr. Zondlo moved to adjourn the meeting, seconded by Dr. Donofrio, unanimously approved at 12:26 p.m.
- The next meeting will be held on Thursday October 2, at 11:30

Respectfully submitted,

*Michelle Ferguson*

Michelle Ferguson
Biosafety Officer

University Biosafety Committee Review Form
For Recombinant DNA Experiments Covered by the
NIH *Guidelines*

**Principal Investigator**: _____Dr. Velia Fowler_____

**Department**: _Biological Sciences

**Project Title**: Properties affecting cell membrane skeleton and cytoskeleton assembly, organization and stability

**Registration Number**: _____25-029 (3 year renewal of 22-016)_____

NIH Guidelines Section: III-D-4; III-E-1; III-E-3; III-E-4

**Description of procedures provided**: Yes __XX__ No _____
TENSIN1 and TMOD1 protein expression and RNA levels increase considerably towards the end of terminal erythroid differentiation. The goal of this project is to learn the function of this protein in erythropoiesis by using CRISPR/Cas9 technology to create a knockout in CD34+ hematopoietic stem cells. Cell line models will be used to test molecular domain functions of TMODs and TNS1 and their binding partners in actin assembly, membrane remodeling, cell adhesion and migration.
Recombinant proteins will also be expressed and purified from bacteria or from eukaryotic cells to investigate domain binding partners and interactions.

**Containment Level**: _____BSL-2_____

**Appropriate facilities to be used**: Yes __XX___ No _____

**Procedures acceptable for containment**: Yes ___XX____ No _____

**Work practices acceptable for containment**: Yes __XX_____ No _____

**Training/ Experience of Personnel acceptable for work**: Yes ___XX____ No ____

**Comments**: The committee agreed with the proposed procedures, work practices and containment. Lab members listed on this protocol have been properly trained with techniques. No concerns were brought up.

These items have been reviewed by the University Biosafety Committee and the committee has voted **__XX_ For** _____ Against approval of this project on this date. (12 for/0 against)
Experiments covered by this protocol can now be initiated.

UBC Representative: _____*Michelle L Ferguson*_____
Date: _____6/5/25_____